<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109615</url>
  </required_header>
  <id_info>
    <org_study_id>2010-018700-90</org_study_id>
    <nct_id>NCT01109615</nct_id>
  </id_info>
  <brief_title>Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations</brief_title>
  <acronym>PG</acronym>
  <official_title>Phase II Study of Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the efficacy and safety of the combination of pemetrexed and&#xD;
      gemcitabine in heavily pre-treated, chemotherapy resistant colorectal cancer patients with&#xD;
      KRAS mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lacking effect of treatment&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Assessed every 3 weeks by CT and/or MR scan and evaluated according to RECIST 1.1. Up to 12 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Every 3 months until progression or death. Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>400 mg/m2 on day 1 of a 3 weeks cycle</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically verified adenocarcinoma in colon or rectum&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  Metastatic colorectal cancer progressed after chemotherapy regimens containing&#xD;
             fluoropyrimidines, oxaliplatin and irinotecan.&#xD;
&#xD;
          -  KRAS mutation in primary tumour or metastasis.&#xD;
&#xD;
          -  Measurable disease according to RECIST&#xD;
&#xD;
          -  ECOG performance status 0, 1 or 2&#xD;
&#xD;
          -  Adequate function of liver, kidneys and bone marrow measured by biochemistry (max. 2&#xD;
             weeks before enrolment)&#xD;
&#xD;
          -  EDTA clearance: Uncorrected GFR &gt; 45 ml/min.&#xD;
&#xD;
          -  Neutrophilocytes ≥1.5 x 10^9/l, leukocytes ≥3.0 x 10^9/l, thrombocytes ≥100x10^9/l&#xD;
&#xD;
          -  ALAT ≤ 3 x upper normal value (ULN), bilirubin ≤ 3 x upper normal value, Aptt and INR&#xD;
             normal (or 2-3 at AC treatment). (ALAT and basic phosphatase ≤ 5 x upper normal value&#xD;
             in case of liver metastases).&#xD;
&#xD;
          -  Blood samples and paraffin embedded tissue from primary tumour and/or metastases for&#xD;
             translational research.&#xD;
&#xD;
          -  Fertile men and women (women &lt;2 year after last menstruation) must use efficient birth&#xD;
             control.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant other concurrent disease making the patient unfit for&#xD;
             participation in the study according to the investigator.&#xD;
&#xD;
          -  Other malignant disease within 5 years prior to study enrolment, except from&#xD;
             planocellular and basal cell carcinomas in the skin or carcinoma-in-situ cervix.&#xD;
&#xD;
          -  Other experimental treatment within 30 days prior to treatment start.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Clinical or radiological signs of CNS metastases.&#xD;
&#xD;
          -  Planned radiation of target lesions.&#xD;
&#xD;
          -  Concurrent vaccination against yellow fever.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Jakobsen, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>April 17, 2012</last_update_submitted>
  <last_update_submitted_qc>April 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>Treatment resistant</keyword>
  <keyword>Chemotherapy refractory</keyword>
  <keyword>KRAS mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

